Ekkospire™ is a biologic treatment for severe asthma — the first of its kind without phenotypic or biomarker limitations, widening access to long-term maintenance treatment.
The challenge: build a visual system that feels both scientifically rigorous and humanly relieving, avoiding the cold, generic codes typical of B2B pharma communication.